A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.
复制标题
DOI：
10.1093/infdis/jiw067
复制
发表时间：
2016-09-15
期刊：
影响因子：
--
通讯作者：
Whitehead, Stephen S
中科院分区：
文献类型：
--
作者：
Durbin, Anna P;Kirkpatrick, Beth D;Whitehead, Stephen S
未贴标：理想的登革热疫苗将提供针对登革热病毒的所有血清型的保护，并且在其施用中将是经济的和简单的。为了确定单剂量的活减毒四价登革疫苗TV003诱导合适的中和抗体应答的能力，在48名健康成人中进行安慰剂对照临床试验，所述健康成人接受间隔12个月施用的2剂疫苗或安慰剂。安全性、疫苗病毒血症和每次接种后的中和抗体应答的评价表明，第一剂疫苗能够预防第二剂疫苗的感染，因此表明多次接种是不必要的。
UNLABELLED: The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary.CLINICAL TRIALS REGISTRATION: NCT01782300.